Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
The so-called mini-Beast from the East has swept in, bringing with it snow, ice and strong winds.
London arts and textiles teacher Andria Zafirakou beat 30,000 others from 170 countries to be crowned winner at the ceremony in Dubai.
The family of a mother and daughter who died in a shooting in St Leonards, Sussex, have described them as "beautiful people".